Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PIT565 |
Synonyms | |
Therapy Description |
PIT565 is a trispecific antibody that targets CD19 expressed on tumor cells, and CD3 and CD2 expressed on T-lymphocytes, potentially leading to tumor cell killing and antitumor activity (Blood (2022) 140 (Supplement 1): 3148). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PIT565 | PIT-565|PIT 565 | CD19 Antibody 21 CD3 Antibody 99 | PIT565 is a trispecific antibody that targets CD19 expressed on tumor cells, and CD3 and CD2 expressed on T-lymphocytes, potentially leading to tumor cell killing and antitumor activity (Blood (2022) 140 (Supplement 1): 3148). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05397496 | Phase I | PIT565 | Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies | Recruiting | USA | ITA | ISR | FRA | ESP | BEL | 2 |